Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of “Moderate Buy” from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $14.8333.

A number of equities analysts have commented on the stock. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Cantor Fitzgerald began coverage on shares of Karyopharm Therapeutics in a report on Thursday, February 5th. They set an “overweight” rating for the company. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Karyopharm Therapeutics in a research note on Monday, December 29th.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC bought a new stake in Karyopharm Therapeutics in the fourth quarter valued at $74,000. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the 2nd quarter worth $45,000. State Street Corp lifted its position in shares of Karyopharm Therapeutics by 27.2% in the 4th quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after purchasing an additional 12,600 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at about $95,000. Finally, XTX Topco Ltd bought a new stake in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $56,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Trading Down 0.6%

Shares of NASDAQ KPTI opened at $8.77 on Monday. The business has a 50-day moving average of $7.76 and a 200-day moving average of $6.77. The firm has a market capitalization of $160.84 million, a price-to-earnings ratio of -0.53 and a beta of 0.13. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The company had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. On average, analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.